Ticker: TSX - TOS
Shares Outstanding: 73,000,906
QUEBEC CITY, Feb. 5, 2014 /CNW Telbec/ - TSO3 Inc. ("TSO3"), an innovator in low-temperature sterilization technology for medical devices in healthcare settings, today announced that the Company has been notified by the European Patent Office of its decision to grant a patent applied for in 2010.
This patent describes a method for controlling condensation of hydrogen peroxide (H2O2) when sterilizing medical devices with hydrogen peroxide, either used alone or in combination with ozone or other chemistries. Several other patent applications covering TSO3's technology are still pending in the United States, Europe, Japan and elsewhere in the world. The Company has also been notified by the Japanese and Australian Patent Offices of their intent to grant two of these other patents.
"TSO3 applied for a portfolio of patents globally in order to protect its new technology. The grant of this patent in Europe as well as the notification of the intent to grant additional patents in Japan and Australia is rewarding. We anticipate additional grants in Europe, Japan, and USA as well as additional markets in the near future" stated Mr. R.M. (Ric) Rumble, President and CEO. "Our unique Dynamic Sterilant Delivery SystemTM is core to our differentiation and its protection enhances the Company's inherent value. Recently TSO3 announced additional patent application in this space targeting methods to improve the compatibility of the sterilization process with delicate medical devices", concluded Mr. Rumble.
TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals. For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
SOURCE: TSO3 Inc.
For further information:
R.M. (Ric) Rumble
President and CEO
(418) 651-0003, Ext. 254
Email: [email protected]